PROACTIF: A prospective, real-world Y-90 study with TheraSphere for the treatment of liver malignancies: Interim data of 168 intrahepatic cholangiocarcinoma (ICC) patients.
Use of TheraSphere in treatment of ICC is outside the labeled indications as safety and effectiveness has not been established.
TheraSphere Y-90 glass microspheres demonstrated overall survival of 18.1 months for 168 ICC patients in PROACTIF.
*Non-malignant thrombus
Appropriately selected ICC patients treated with TheraSphere demonstrated an overall survival of 18.1 months using Y-90. This dataset helps build foundational real-world data for an under-studied disease state.
This study is sponsored by Boston Scientific. Final results are expected in 2025 and will include full patient population with additional information on quality of life, safety and dosimetry.
Garin E, Brenot-Rossi I, Tlili G et al. Abstract 222.4 Treatment of intrahepatic cholangiocarcinoma with Y-90 glass microspheres in the PROACTIF study. ECIO 2024 Book of Abstracts. Cardiovasc Intervent Radiol 47 (Suppl 4); 2024. p.60 https://doi.org/10.1007/s00270-024-03732-x
Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators. Boston Scientific’s involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge about our products. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.
Use of TheraSphere in treatment of ICC is outside the labeled indications as safety and effectiveness has not been established.
TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.
